Your Blood Knows

You're reading the first issue of The Lifespan Daily - a newsletter about the science, business, and daily practice of living longer and better.

Not the "biohacker bro" version. Not the supplement-shilling version. The version where we track what the research actually says, who's funding the science, and what you can do about it today.

Every week, we break down the longevity breakthroughs that matter - the ones backed by data, not marketing. If a drug worked, a trial failed, or a billionaire bet big on age reversal - you'll hear about it here.

Let's get into it.

Life Biosciences - co-founded by Harvard geneticist Dr. David Sinclair - has received FDA approval to begin first-in-human clinical trials for ER-100, a partial epigenetic reprogramming therapy.

The initial trial targets optic neuropathies (age-related vision loss). But the underlying technology is far more ambitious: resetting cellular age by reprogramming the epigenome - the switches that control which genes are active in your cells.

What epigenetic reprogramming means: As you age, your cells accumulate "epigenetic noise" - chemical modifications that cause genes to turn on or off at the wrong times. Reprogramming aims to reset these switches to a younger state without changing your DNA.

The lab results so far:

Why this matters: This isn't a supplement or a lifestyle hack. This is the first time a therapy designed specifically to reverse biological aging has entered regulated human trials. If it works - even partially - it changes the entire conversation about what aging is: not an inevitability, but a treatable condition.

The longevity market is projected to reach $610 billion by 2030. ER-100 is the first real clinical test of whether the science matches the investment.

That's how much biological age reduction a new study found in adults who took a daily multivitamin for two years - measured by epigenetic clock analysis of blood samples.

Published in early 2026, the randomized clinical trial showed that participants taking a standard daily multivitamin had measurably younger biological age markers compared to the placebo group.

What this means practically: You don't need a $10,000 longevity protocol to move the needle. A $15/month multivitamin produced a statistically significant reduction in biological aging. The effect is modest - but it's real, it's cheap, and it's available now.

This doesn't mean multivitamins are the answer to aging. It means the bar for "doing something" is lower than the longevity industry wants you to believe.

A study published in Aging Cell this month revealed that rilmenidine - a widely available blood pressure medication - can slow the effects of aging and extend lifespan in animal models by mimicking calorie restriction.

Calorie restriction is the most consistently proven intervention for extending lifespan across species. The problem: nobody wants to be hungry forever. Rilmenidine appears to trigger the same cellular pathways without the starvation.

The details:

The caveat: Animal results don't always translate to humans. But rilmenidine's existing safety profile and low cost make it a strong candidate for human longevity trials - which multiple research groups are now designing.

Research published in February 2026 found that the shingles vaccine (Shingrix) may slow biological aging and reduce systemic inflammation in adults 70 and older.

The study measured epigenetic age markers before and after vaccination. The vaccinated group showed a measurable reduction in biological age acceleration compared to unvaccinated controls.

The hypothesis: Chronic viral reactivation (like shingles from dormant varicella-zoster virus) drives inflammation that accelerates aging. By preventing reactivation, the vaccine reduces this inflammatory burden - with downstream effects on biological age.

This is part of a growing body of evidence that managing chronic infection and inflammation may be one of the most underrated longevity interventions available. No special clinic required. Just your pharmacy.

A March 2026 paper in Nature Aging demonstrated that gut microbiota composition is not just correlated with biological age - it's causally linked. Researchers transferred gut bacteria from young mice to aged mice and observed:

What this means for humans: Your gut microbiome isn't just affecting your digestion - it's actively influencing how fast you age. The companies racing to commercialize this include Seed Health, Pendulum Therapeutics, and several stealth-mode startups.

The practical takeaway: fiber intake, fermented foods, and microbiome diversity aren't wellness trends. They're longevity interventions with causal evidence behind them.

A snapshot of the numbers that drive the longevity economy:

Longevity science left the lab. The money is real - $5.2 billion in VC funding last year, sovereign wealth funds betting billions more, and the first age-reversal drugs entering human trials.

Most coverage of this space falls into two categories: breathless hype or impenetrable academic papers. The Lifespan Daily exists to sit in the middle - tracking what's real, what works, and what it costs.

Every week, we cover the science, the money, and the practical steps. Because living longer isn't a fantasy anymore. It's an industry.

See you next week.

- The Lifespan Daily

Like this? Forward it to someone who wants to live longer - and smarter. They'll thank you.